Standard BioTools Inc. (LAB)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 85,331,000 -6.2%
- Net income
- -74,896,000
- Gross profit
- 42,543,000
- Operating income
- -110,249,000
- Earnings per share
- -0.20
- R&D expense
- 25,987,000
Growth and profitability
- Gross margin
- 49.86
- Operating margin
- -129.20
- Net margin
- -87.77
- Return on equity
- -17.65
- Return on assets
- -13.19
- Free cash flow margin
- -96.85
Balance sheet
- Total assets
- 567,754,000
- Total liabilities
- 143,463,000
- Shareholders' equity
- 424,291,000
- Cash and equivalents
- 120,863,000
- Current ratio
- 4.19
Cash flow and ratios
- Operating cash flow
- -74,343,000
- Free cash flow
- -82,646,000
Shareholder returns
- Share buybacks
- 0
- Shares outstanding
- 394,790,441
- Book value per share
- 1.07
Company information
- Headquarters
- Boston, MA
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Standard BioTools Inc. trades on NASDAQ under the ticker symbol LAB. This page brings together its price chart, company profile, key financial figures and technical indicators.